Popular Joint Supplement Linked to Higher Dementia Risk

Glucosamine is one of the most widely used supplements in America. Millions of people take it daily for joint pain and arthritis. A new study from the University of Florida is raising concerns — but the researchers are being very careful about who actually needs to worry.

The study found that people with mild cognitive impairment who used glucosamine were 25% more likely to progress to an Alzheimer's diagnosis. They were also 25% more likely to die within a specified timeline. Those numbers sound alarming. The context matters enormously.

"For a healthy older adult taking glucosamine for their knees, our data show no signal of harm, and they should not be alarmed by this study," said senior author Ramon Sun, director of the Center for Advanced Spatial Biomolecule Research at UF's McKnight Brain Institute. "The concern is narrower. In a brain that already has Alzheimer's pathology, glucosamine appears to feed the very process that is driving the disease."

In other words — if you're healthy and taking glucosamine for your joints, this study is not about you. If you already have mild cognitive impairment or early Alzheimer's pathology, it may be worth a conversation with your doctor.

What's Actually Happening in the Brain

The mechanism the researchers identified involves sugar tagging — a natural process where sugar molecules attach to proteins and fats inside cells. This process is normal and necessary. The problem is that glucosamine is a sugar-like molecule that appears to be able to cross the blood-brain barrier and make this sugar-tagging process overactive.

In a brain that's already dealing with Alzheimer's pathology, that overactive sugar tagging appears to accelerate the disease. The researchers confirmed this in mice — animals given glucosamine showed greater memory and recognition deficits, and when the supplement was removed their memory improved.

Sun was emphatic that the research came from following the chemistry, not from suspicion about the supplement. "We honestly were not setting out to indict glucosamine," he said. "We were following the chemistry, and it pointed us there."

Why This Research Is Different

What makes this study notable beyond the finding itself is the technology used to make it. Sun's lab developed a new spatial measurement tool that can track thousands of different molecules at every point across a slice of brain tissue — essentially mapping where everything is located rather than averaging results across the whole brain.

That distinction matters because Alzheimer's is a localized disease. Changes that look small when averaged across an entire brain can be enormous in the specific areas that drive the disease. Previous research methods were essentially blurring those crucial details. This technology lets researchers see them clearly.

"A change that looks small when you average across the whole brain can be enormous in the one spot that counts, and standard methods average it away," Sun said.

The Unexpected Upside

Here's where the story takes an interesting turn. The same pathway that glucosamine appears to activate in vulnerable brains also represents a completely new therapeutic target for Alzheimer's treatment.

When researchers turned down the sugar-tagging pathway in mice their memory improved — and it did so through a mechanism entirely separate from amyloid plaques, which have been the dominant focus of Alzheimer's research and drug development for decades. Multiple high-profile amyloid-targeting drugs have failed in clinical trials, making new pathways genuinely exciting to researchers.

"So this is really a story about understanding Alzheimer's as a disease of metabolism, which opens a door we have not fully walked through yet," Sun said.

What You Should Do With This Information

If you're a healthy adult taking glucosamine for knee pain or joint stiffness — don't panic. The study found no harm signal for people without existing cognitive impairment. Keep taking it if it's helping you.

If you or someone you care for has been diagnosed with mild cognitive impairment or early-stage Alzheimer's and is taking glucosamine — that's worth bringing up with a neurologist or primary care physician. The risk identified in this study is real and specific to that population. A doctor can help weigh whether the joint benefits outweigh the potential cognitive concerns for that individual situation.

The supplement industry moves fast and the research rarely keeps pace. This is one of the cases where the science caught up to something millions of people are already doing — and found that for most of them it's fine, but for a specific and vulnerable group it may not be.

Curious for more stories that keep you informed and entertained? From the latest headlines to everyday insights, YourLifeBuzz has more to explore. Dive into what’s next.